Anti-Bcl2 therapy in chronic myelogenous leukemia.
Smith
Sonali
S
Lymphoma Program, The University of Chicago, Chicago, IL, USA.
D002986:Clinical Trials as Topic; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D013873:Thionucleotides / Q000627:therapeutic use; D016896:Treatment Outcome
D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; C408162:oblimersen